BR9509730A - Compostos polinucleotidíeos - Google Patents

Compostos polinucleotidíeos

Info

Publication number
BR9509730A
BR9509730A BR9509730A BR9509730A BR9509730A BR 9509730 A BR9509730 A BR 9509730A BR 9509730 A BR9509730 A BR 9509730A BR 9509730 A BR9509730 A BR 9509730A BR 9509730 A BR9509730 A BR 9509730A
Authority
BR
Brazil
Prior art keywords
provides
polynucleotide
another aspect
block
polyether
Prior art date
Application number
BR9509730A
Other languages
English (en)
Inventor
Alexander Victorvich Kabanov
Valery Yulievich Alakhov
Sergey Y Vinogradov
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of BR9509730A publication Critical patent/BR9509730A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
BR9509730A 1994-11-18 1995-11-17 Compostos polinucleotidíeos BR9509730A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/342,209 US5656611A (en) 1994-11-18 1994-11-18 Polynucleotide compositions
PCT/US1995/013800 WO1996015778A1 (en) 1994-11-18 1995-11-17 Polynucleotide compositions

Publications (1)

Publication Number Publication Date
BR9509730A true BR9509730A (pt) 1997-09-30

Family

ID=23340835

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509730A BR9509730A (pt) 1994-11-18 1995-11-17 Compostos polinucleotidíeos

Country Status (13)

Country Link
US (1) US5656611A (pt)
EP (1) EP0789564B1 (pt)
JP (1) JPH10509048A (pt)
CN (1) CN1173128A (pt)
AT (1) ATE321133T1 (pt)
AU (1) AU716453B2 (pt)
BR (1) BR9509730A (pt)
CA (1) CA2205486A1 (pt)
DE (1) DE69534895T2 (pt)
ES (1) ES2260765T3 (pt)
NZ (1) NZ297164A (pt)
RU (1) RU2175337C2 (pt)
WO (1) WO1996015778A1 (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380536A (en) 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
US6933286B2 (en) * 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
WO2003011008A2 (en) * 2001-07-31 2003-02-13 Cyrx Corporation Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
JP2690276B2 (ja) * 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
EP0935415B1 (en) * 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro methods for delivering nucleic acids into a cell
WO1997045069A1 (en) * 1996-05-29 1997-12-04 Cell Genesys, Inc. Cationic polymer/lipid nucleic acid delivery vehicles
EP0934082B1 (de) * 1996-10-23 2002-07-17 SKW Trostberg Aktiengesellschaft Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten
US5908845A (en) * 1996-10-30 1999-06-01 Segev; David Polyether nucleic acids
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
CA2298061A1 (en) * 1997-08-01 1999-02-11 Supratek Pharma, Inc. Polynucleotide compositions
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
EP0963758A3 (en) * 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
GB9913359D0 (en) 1999-06-09 1999-08-11 Cancer Res Campaign Tech Polymer modified biological elements
US6348583B1 (en) * 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
CN101011584A (zh) * 1999-12-28 2007-08-08 诺瓦提斯公司 获得持续的转基因表达的方法
EP1242609A2 (en) * 1999-12-30 2002-09-25 Novartis AG Novel colloid synthetic vectors for gene therapy
WO2001065911A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
US6875748B2 (en) * 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20020042388A1 (en) * 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
AU2001270147A1 (en) * 2000-06-23 2002-01-08 Merck & Co., Inc. Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
EP1309650A2 (en) 2000-08-18 2003-05-14 University Of North Carolina At Chapel Hill Compositions of nucleic acids that form molten phases and methods of use thereof
CA2422524A1 (en) 2000-09-25 2002-03-28 Motoyuki Yamashita Pei: dna vector formulations for in vitro and in vivo gene delivery
CA2436665C (en) 2001-01-29 2012-01-10 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US7151139B2 (en) * 2001-04-23 2006-12-19 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
WO2002085542A1 (en) * 2001-04-23 2002-10-31 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
US9089407B2 (en) 2001-04-23 2015-07-28 Massachusetts Institute Of Technology Antibacterial coatings that inhibit biofilm formation on implants
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US20030138407A1 (en) * 2001-11-02 2003-07-24 Patrick Lu Therapeutic methods for nucleic acid delivery vehicles
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
FR2835749B1 (fr) 2002-02-08 2006-04-14 Inst Nat Sante Rech Med Composition pharmaceutique ameliorant le transfert de gene in vivo
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ATE486613T1 (de) * 2002-03-07 2010-11-15 Biocompatibles Uk Ltd Mit nucleinsäure complexierte block-copolymere
US20040102608A1 (en) * 2002-05-13 2004-05-27 Cornell Research Foundation, Inc. Multiblock copolymers having improved mechanical properties
AR037006A1 (es) * 2002-06-20 2004-10-20 S I G Sist S De Identificacion Marcador de objetos a identificar consistente en al menos un fragmento de adn.
MX367615B (es) 2002-09-06 2019-08-28 Cerulean Pharma Inc Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
EP1578193A4 (en) * 2002-12-23 2011-06-15 Vical Inc FREEZING PROCESS FOR NUCLEIC ACID / BLOCK COPOLYMER / CATION SIDE COMPLEXES
WO2004060363A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for producing sterile polynucleotide based medicaments
EP1587816B1 (en) 2002-12-23 2010-06-16 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7682626B2 (en) * 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
RU2394041C2 (ru) 2003-04-13 2010-07-10 Энзон Фармасьютикалз, Инк. Полимерные олигонуклеотидные пролекарства
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2004105799A1 (ja) * 2003-05-29 2004-12-09 Toudai Tlo, Ltd. 安定化高分子ミセル
ATE432095T1 (de) * 2003-09-25 2009-06-15 Wageningen Universiteit Agrote Mizellen mit einem komplexkoazervatkern als fäulnishemmende mittel
EP1737899B1 (en) * 2004-04-20 2015-07-08 Dendritic Nanotechnologies, Inc. Dendritic polymers with enhanced amplification and interior functionality
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
US7422875B2 (en) * 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
AU2005289520A1 (en) * 2004-09-27 2006-04-06 Vical Incorporated Formulations and methods for treatment of inflammatory diseases
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
WO2006130709A2 (en) * 2005-06-01 2006-12-07 Rhodia Inc. Coacervate systems having soil anti-adhesion and anti-deposition properties on hydrophilic surfaces
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US9090648B2 (en) * 2005-12-15 2015-07-28 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
JP2010504318A (ja) * 2006-09-22 2010-02-12 ラボファーム インコーポレイテッド ｐＨ標的化薬剤送達のための組成物及び方法
EP2084234A2 (en) * 2006-11-08 2009-08-05 Massachusetts Institute of Technology Polymeric coatings that inactivate viruses and bacteria
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
WO2008141275A1 (en) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
KR20110095292A (ko) * 2008-11-06 2011-08-24 유니버시티 오브 워싱톤 다중블록 공중합체
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
EP2569434B1 (en) 2010-05-14 2019-09-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia and related disorders
US9320814B2 (en) * 2011-11-01 2016-04-26 Board Of Regents Of The University Of Nebraska Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
CA2856116A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
CA2856117A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
US9556432B2 (en) 2012-01-10 2017-01-31 The Research Foundation For The State University Of New York Method of treating hyperlipidemia and atherosclerosis with miR-30C
EP3971571A3 (en) 2012-05-25 2022-06-08 The University of Vermont and State Agriculture College Compositions and methods for assaying platelet reactivity and treatment selection
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP3034539A1 (en) * 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
EP3386594B1 (en) 2015-12-11 2023-05-03 The General Hospital Corporation Combination of a platelet-derived growth factor receptor alpha inhibitor and a histone lysine demethylase inhibitor for treating drug-tolerant glioblastoma
CA3096274A1 (en) 2018-04-06 2019-10-10 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
WO2021248052A1 (en) 2020-06-05 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating neoplasia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944489A (ja) * 1982-09-07 1984-03-12 帝国石油株式会社 原油回収用ミセル溶液組成物
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
EP0262516A2 (en) * 1986-09-29 1988-04-06 Miles Inc. Genetic transformation of lactic acid bacteria
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
DE69431959T2 (de) * 1993-10-15 2003-11-06 Cytrx Corp Therapeutische abgabesysteme und verfahren für ihre verwendung

Also Published As

Publication number Publication date
WO1996015778A1 (en) 1996-05-30
CN1173128A (zh) 1998-02-11
CA2205486A1 (en) 1996-05-30
RU2175337C2 (ru) 2001-10-27
EP0789564A4 (en) 2000-11-08
ES2260765T3 (es) 2006-11-01
ATE321133T1 (de) 2006-04-15
EP0789564A1 (en) 1997-08-20
JPH10509048A (ja) 1998-09-08
DE69534895D1 (de) 2006-05-11
AU716453B2 (en) 2000-02-24
NZ297164A (en) 2000-01-28
AU4196596A (en) 1996-06-17
DE69534895T2 (de) 2006-11-09
US5656611A (en) 1997-08-12
EP0789564B1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
BR9509730A (pt) Compostos polinucleotidíeos
EP1439195A3 (fr) Polymères hydrosolubles résiduels a faible teneur en monomères et leurs utilisations
CA2173878A1 (en) Polynucleotide for Treating Systemic Lupus Erythematosus
ATE231891T1 (de) Supramolekular polymere
BR9911754A (pt) Copolìmero linear de ciclodextrina, composição terapêutica, composição de ciclodextrina, processos de preparo de um copolìmero linear de ciclodextrina, e de um copolìmero linear de ciclodextrina oxidada, processo para produzir um polìmero reticulado de ciclodextrina, e, processo de tratamento
EP0359996A3 (en) Synthetic amino acid-and/or peptide-containing graft copolymers
MY118538A (en) Polymeric compositions and their production and uses
BR8406665A (pt) Composicao de polimero compatibilizada e copolimero de enxerto
MX9206247A (es) Agentes de transferencia de cadena de mercaptano latentes de tiol y su empleo en la sintesis de polimeros.
MX220853B (es) Hidrogeles hidrofilicos, con alta capacidad de hinchado, su preparacion y uso
AU2001285891A1 (en) Use of hydrophilic graft copolymers with n-vinylamine and/or open-chained n-vinylamide units in cosmetic formulations
EP0200548A3 (en) Deodorant compositions containing cationic polymers
CA2138314A1 (en) Acrylamide Polymers and Use Thereof
AU1843792A (en) Composition for washing and/or conditioning keratinous matter, containing a silicone and an amphoteric polymer derived from diallyldialkylammonium and from an anionic monomer
DE69708304T2 (de) Vernetzte copolymere auf der basis von polycarbonsäurepolymeren
FR2761599B1 (fr) Compositions cosmetiques contenant un polymere cationique de faible masse moleculaire et leurs utilisations
DE69112420D1 (de) Makromolekulare monomere aus lebenden polymeren.
GB9506806D0 (en) Improvements relating to polymers
EP0416496A3 (en) Blends of carbonate polymer, polyacetal and compatibilizer
FR2769316B1 (fr) Copolymere greffe par polymerisation radicalaire en presence de radicaux stables, sa preparation et ses applications
WO1997049718A3 (fr) Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations
CA1272329C (en) HIGHLY HYGROSCOPIC SOFT CONTACT LENSES
DE69014655D1 (de) Schlagfeste Polymermischungen aus Polyamiden, Anhydridcopolymeren und funktionalisierten Elastomeren.
ATE229315T1 (de) Zusammensetzungen enthaltend filmbildende schweisshemmende polymere
DE69430261D1 (de) Thermotrope poly(esteramide)e enthaltende monomereinheiten abgeleitet aus 4,4'-biphenyldicarbonsäure

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]